Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country
Open Access
- 1 February 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2300281
Abstract
PURPOSE: Myelodysplastic syndromes (MDS) include a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis. They manifest as dysplasia in bone marrow hemopoietic elements associated with peripheral cytopenias with variable risk of AML transformation. PATIENTS AND METHODS: We analyzed retrospectively registry data collected prospectively from patients with primary MDS and patients with MDS/myeloproliferative neoplasm (MPN) in the Jordan University Hospital between January 2007 and September 2021. The registry captured epidemiologic information such as date of diagnosis, age, gender, date of AML transformation, cytogenetics, MDS subtype, risk group according to Revised International Prognostic Scoring System, and survival. The registry also captured baseline ferritin, B12, and lactate dehydrogenase levels. RESULTS: A total of 112 patients with MDS and MDS/MPN were included in the registry. Median age at diagnosis was 59 years. The male-to-female ratio was about 1.2. In a multivariate cox regression model, baseline serum ferritin significantly affected survival as patients with levels exceeding 1,000 μg/L had a risk of death three times higher compared with those with <1,000 μg/L levels ( P < .05). CONCLUSION: To our knowledge, our study is the first comprehensive study examining the epidemiology and prognostic factors in patients with MDS and patients with MDS/MPN in Jordan. Our results show that MDS and MDS/MPN epidemiology in Jordan is different compared with Western countries. Our results also show that baseline serum ferritin levels can be used as a prognostic marker for patients with MDS.Keywords
This publication has 49 references indexed in Scilit:
- Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming itBlood Reviews, 2019
- Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromesAnnals of Hematology, 2018
- To chelate or not to chelate in MDS: That is the question!Blood Reviews, 2018
- Cytogenetic features in primary myelodysplastic syndrome Egyptian patientsJournal of Advanced Research, 2018
- A storm in the niche: Iron, oxidative stress and haemopoiesisBlood Reviews, 2018
- Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromesAmerican Journal of Hematology, 2013
- The incidence of myelodysplastic syndromes in Western Greece is increasingAnnals of Hematology, 2013
- Epidemiology of Myelodysplastic SyndromesThe American Journal of Medicine, 2012
- Myelodysplastic syndromesCancer, 2007
- Young age MDS: Differences between Western and Eastern countriesLeukemia Research, 2006